Low CD4+ T-cell levels and B-cell apoptosis in vertically HIV-exposed noninfected children and adolescents.
Lymphocyte subsets, activation markers and apoptosis were assessed in 20 HIV-exposed noninfected (ENI) children born to HIV-infected women who were or not exposed to antiretroviral (ARV) drugs during pregnancy and early infancy. ENI children and adolescents were aged 6-18 years and they were compared to 25 age-matched healthy non-HIV-exposed children and adolescents (Control). ENI individuals presented lower CD4(+) T cells/mm(3) than Control group (control: 1120.3 vs. ENI: 876.3; t-test, p = 0.030). ENI individuals had higher B-cell apoptosis than Control group (Control: 36.6%, ARV exposed: 82.3%, ARV nonexposed: 68.5%; Kruskal-Wallis, p < 0.05), but no statistical difference was noticed between those exposed and not exposed to ARV. Immune activation in CD4(+) T, CD8(+) T and in B cells was comparable in ENI and in Control children and adolescents. Subtle long-term immune alterations might persist among ENI individuals, but the clinical consequences if any are unknown, and these children require continued monitoring.
Miyamoto
Maristela
M
Division of Pediatric Infectious Diseases, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil.
Pessoa
Silvana D
SD
Ono
Erika
E
Machado
Daisy M
DM
Salomão
Reinaldo
R
Succi
Regina C de M
RC
Pahwa
Savita
S
de Moraes-Pinto
Maria Isabel
MI
D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000502:physiology; D001402:B-Lymphocytes / Q000276:immunology; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016022:Case-Control Studies; D002648:Child; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000635:transmission*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D011247:Pregnancy / Q000276:immunology; D019562:Viral Load
D044966:Anti-Retroviral Agents
Immunol Lett. 1999 Mar;66(1-3):97-103
10203040
J Clin Virol. 2005 Apr;32(4):329-35
15780814
Braz J Med Biol Res. 2008 Aug;41(8):700-8
18797705
Clin Infect Dis. 2005 Feb 1;40(3):458-65
15668871
Antimicrob Agents Chemother. 2007 Dec;51(12):4236-42
17893156
Lancet. 1999 Sep 25;354(9184):1084-9
10509500
Clin Vaccine Immunol. 2006 Feb;13(2):246-52
16467333
Pharmacology. 2008;82(2):83-8
18504416
Clin Diagn Lab Immunol. 1998 Mar;5(2):230-4
9521148
Blood. 2002 Aug 15;100(4):1381-7
12149221
J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):429-34
11981357
Blood. 2001 Jul 15;98(2):398-404
11435309
J Allergy Clin Immunol. 2003 Nov;112(5):973-80
14610491
Blood. 2003 Jun 1;101(11):4260-6
12576317
Pediatrics. 2007 Mar;119(3):e694-704
17296782
Pediatrics. 1994 Apr;93(4):624-30
8134219
Blood. 2000 Dec 1;96(12):3866-71
11090071
AIDS. 2005 Jan 3;19(1):15-23
15627029
AIDS. 2009 Jan 2;23(1):35-40
19050384
Clin Diagn Lab Immunol. 1997 May;4(3):358-61
9144377
J Trop Pediatr. 2010 Apr;56(2):75-81
19602487
Cell Death Differ. 1997 Dec;4(8):699-706
16465282
Braz J Infect Dis. 2004 Apr;8(2):140-50
15361992
Nat Med. 1995 May;1(5):417-22
7585087
Blood. 2002 Mar 1;99(5):1666-75
11861282
Antivir Ther. 2004 Apr;9(2):197-204
15134181
Med Chem. 2008 Jan;4(1):75-9
18220972